** Shares of Lumos Diagnostics LDX.AX rise as much as 12.8% to A$0.265, highest level since May 12, 2022
** Q1 product revenue rises four-fold to $1.2 million, helped by increasing adoption of FebriDx across the U.S.
** FebriDx is co's rapid point of care test to help differentiate between bacterial and non-bacterial acute respiratory infections
** YTD, shares have risen more than seven-fold in value
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com))